文献速递免疫规划传染病防控与疫情报告

基于乙肝核心病毒样颗粒的RSV疫苗诱导黏膜免疫

Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity.
PubMed 文献 · Vaccine · 2021-05-08

研究构建含RSV F蛋白两个七肽重复区及抗原位点Ø、II、IV的重组疫苗候选HRØ24,与乙肝核心蛋白病毒样颗粒(HBc VLPs)混合后经鼻内免疫BALB/c和C57BL/6小鼠。结果显示可诱导血清IgG和肺sIgA,免疫反应偏向Th1,RSV A2株攻击后体重丢失<5%且嗜酸性粒细胞浸润无至低,提示部分保护。

要点

  • HBc VLPs/HRØ24经鼻免疫诱导小鼠血清IgG和肺sIgA。
  • 免疫反应Th1偏向,IFN-γ分泌增加、IgG2a/IgG1比值升高。
  • RSV攻击后体重丢失<5%,肺部嗜酸性粒细胞浸润无至低。

核心结论

  • HBc VLPs与HRØ24混合经鼻接种可在小鼠模型实现对RSV所致疾病的长期免疫。

研究设计与样本

  • 构建、表达并纯化含RSV F蛋白两个七肽重复区及抗原位点Ø、II、IV的重组疫苗候选HRØ24。
  • 将HRØ24与HBc VLPs混合经鼻内给予BALB/c和C57BL/6小鼠,评估黏膜免疫。

主要发现

  • 经鼻给予HBc VLPs联合HRØ24在C57BL/6和BALB/c小鼠均诱导针对HRØ24的血清IgG及肺HRØ24特异性sIgA。
  • 脾细胞再刺激IFN-γ分泌及血清IgG2a/IgG1比值升高提示免疫反应Th1偏向。
  • RSV A2株攻击后体重丢失<5%,肺组织学分析嗜酸性粒细胞浸润无至低。

临床怎么用

  • 提示经鼻黏膜接种HBc VLPs/HRØ24或可成为RSV疫苗诱导平衡免疫的策略。

局限性

  • 研究仅在小鼠模型进行,尚未提供人体临床数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) is an important viral pathogen responsible for severe infection of the lower respiratory tract in children under the age of 5 years. No vaccines against RSV are currently in clinical use. Vaccine-associated enhanced respiratory disease (ERD) caused by excess Th2 type responses was observed in a clinical trial of formalin-inactivated RSV (FI-RSV) in antigen-naïve infants. Thus, inducing a balanced immune response is a crucial issue in the development of an RSV vaccine. METHODS: In this study, we constructed, expressed, and purified a recombinant RSV vaccine candidate (i.e., HRØ24) containing the two heptad repeat regions and the antigenic sites Ø, II, and IV of the RSV F protein. The RSV vaccine candidate was intranasally administrated to BALB/c and C57BL/6 mice in combination with virus-like particles (VLPs) derived from the core protein of the hepatitis B virus (HBc). Mucosal immunity to HRØ24 was then assessed. RESULTS: Intranasal administration of HBc VLPs in combination with HRØ24 induced serum IgGs against HRØ24 as well as lung HRØ24-specific sIgAs in both C57BL/6 and BALB/c mouse models. The secretion of IFN-γ from splenocyte re-stimulation and an elevated ratio of serum IgG2a to IgG1 indicated that the immune response induced by the HBc VLPs/HRØ24 mixture was Th1-biased. Weight loss of <5% and no to low eosinophil infiltration was observed in histological analysis of the lung following a challenge with the RSV A2 strain. These results suggest that the HBc VLPs/HRØ24 combination conferred substantial partial protection against RSV-induced illness in mice. CONCLUSIONS: Long-term immunity to RSV-induced illness was achieved via intranasal vaccination using a mixture of HBc VLPs and HRØ24 in mouse models.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Huang JM, Wang SY, Lai MR, et al. Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity. Vaccine. 2021. PMID: 33972124. doi:10.1016/j.vaccine.2021.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。